JP2025511000A5 - - Google Patents

Info

Publication number
JP2025511000A5
JP2025511000A5 JP2024557573A JP2024557573A JP2025511000A5 JP 2025511000 A5 JP2025511000 A5 JP 2025511000A5 JP 2024557573 A JP2024557573 A JP 2024557573A JP 2024557573 A JP2024557573 A JP 2024557573A JP 2025511000 A5 JP2025511000 A5 JP 2025511000A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antigen
binding molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024557573A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511000A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/057751 external-priority patent/WO2023186756A1/en
Publication of JP2025511000A publication Critical patent/JP2025511000A/ja
Publication of JP2025511000A5 publication Critical patent/JP2025511000A5/ja
Pending legal-status Critical Current

Links

JP2024557573A 2022-03-28 2023-03-27 インターフェロンガンマバリアントおよびこれを含む抗原結合分子 Pending JP2025511000A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22164773 2022-03-28
EP22164773.8 2022-03-28
PCT/EP2023/057751 WO2023186756A1 (en) 2022-03-28 2023-03-27 Interferon gamma variants and antigen binding molecules comprising these

Publications (2)

Publication Number Publication Date
JP2025511000A JP2025511000A (ja) 2025-04-15
JP2025511000A5 true JP2025511000A5 (enExample) 2026-04-02

Family

ID=80978821

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024557573A Pending JP2025511000A (ja) 2022-03-28 2023-03-27 インターフェロンガンマバリアントおよびこれを含む抗原結合分子

Country Status (5)

Country Link
US (1) US20250333542A1 (enExample)
EP (1) EP4499229A1 (enExample)
JP (1) JP2025511000A (enExample)
CN (1) CN119095880A (enExample)
WO (1) WO2023186756A1 (enExample)

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
CA2293829C (en) 1997-06-24 2011-06-14 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DE69840412D1 (de) 1997-10-31 2009-02-12 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP1135415B1 (en) 1998-12-01 2010-08-11 Facet Biotech Corporation Humanized antibodies to gamma-interferon
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU6117000A (en) 1999-07-26 2001-02-13 Genentech Inc. Novel polynucleotides and method of use thereof
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
EP1641818B1 (en) 2003-07-04 2008-12-03 Affibody AB Polypeptides having binding affinity for her2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
PT1692182E (pt) 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
WO2005056764A2 (en) 2003-12-05 2005-06-23 Compound Therapeutics, Inc. Inhibitors of type 2 vascular endothelial growth factor receptors
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
SG187746A1 (en) 2010-08-13 2013-03-28 Roche Glycart Ag Anti-fap antibodies and methods of use
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
US20180057603A1 (en) 2013-08-09 2018-03-01 The Trustees Of The University Of Pennsylvania Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers
CA2951604A1 (en) 2014-08-29 2016-03-03 Pablo Umana Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
EP3243836A1 (en) * 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
EP3703746A1 (en) * 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG Novel tnf family ligand trimer-containing antigen binding molecules
EP4314032A1 (en) * 2021-03-30 2024-02-07 F. Hoffmann-La Roche AG Protease-activated polypeptides

Similar Documents

Publication Publication Date Title
ES2439802T3 (es) Anticuerpos tri- o tetraespecíficos
JP2023178323A5 (enExample)
CN103068846B9 (zh) 包含二硫键稳定性Fv片段的双特异性抗体
IL272747B1 (en) Bispecific antibodies 1 + 2
TW202227491A (zh) 抗ror1抗體及相關雙特異性結合蛋白
IL292780A (en) A new 4-1bbl trimer containing antigen-binding molecules
TW201111394A (en) Bispecific, tetravalent antigen binding proteins
JP2025160226A5 (enExample)
AU2005214988A1 (en) Super-humanized antibodies against respiratory syncytial virus
US20230192887A1 (en) Engineered anti-her2 bispecific proteins
JP2023511376A5 (enExample)
JP2024532489A5 (enExample)
JP2022538222A5 (enExample)
TW201113037A (en) Antibodies against CDCP1 for the treatment of cancer
JP2023531494A5 (enExample)
CN1381461A (zh) 抗人肝癌单克隆抗体HAb18轻、重链可变区基因及其应用
JP2022521305A (ja) 抗pd-l1抗体及びその使用
WO2025041097A1 (en) Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof
JPWO2022224997A5 (enExample)
EP4559932A1 (en) Multispecific antibody and use thereof
CN112500491B (zh) 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途
WO2024061224A1 (zh) 抗her2抗体及其用途
JP2024504931A5 (enExample)
US20260109781A1 (en) Anti-her2 antibodies and methods of use thereof
US20240392035A1 (en) Engineered anti-her2 bispecific proteins